Levels of Myeloperoxidase, Malondialdehyde and Lipid Profile in Type 2 Diabetic Patients on Metformin Versus Glibenclamide Therapy
Zainab H. Fathi, Jehan A. Mohammad, Marwah H. Mohammed
In diabetes mellitus, oxidative stress plays a major role in the development and progression of cardiovascular complications. Atherogenic index of plasma is a novel marker to predict the risk of atherosclerotic cardiovascular disease. Our study investigating the effects of metformin and glibenclamide on the levels of myeloperoxidase, malondialdehyde and lipid profile as well as identifying the correlations among these parameters in patients with type 2 diabetic mellitus. Materials and Methods: This study was carried out among 51 patients diagnosed with type 2 diabetic mellitus at Al-Wafaa Center in Mosul, between November 2019 and March 2020. We classified patients into three groups: newly diagnosed diabetic group, metformin receiving group and glibenclamide receiving group for up to 1 year. Then, plasma myeloperoxidase, malondialdehyde, atherogenic index and lipids levels were assessed. Results: Compared with glibenclamide, metformin receiving group revealed a significant reduction in myeloperoxidase, malondialdehyde, atherogenic index and lipid profile indices. The variation of plasma myeloperoxidase and malondialdehyde levels between metformin- and glibenclamide-receiving patients was statistically significant. However, the variation of atherogenic index and plasma lipid profile between treatment groups was non-significant. Moreover, serum myeloperoxidase level has been found to be positively correlated with malondialdehyde, low-density lipoprotein and total cholesterol in diabetic patients. As well, malondialdehyde bioavailability positively correlated with plasma triglyceride, very low-density lipoprotein levels and homeostatic model assessment of insulin resistance in glibenclamide treated patients. However, no statistically significant correlations have been found after using metformin. Conclusion: Metformin has cardio protective effects in diabetic patients, including reduced oxidative stress and improved dyslipidaemia, beyond its antihyperglycemic activity.